poisar

Stocks · News reference

Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK Inhibitors

Benzinga Newsdesk

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IMRX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Immuneering Corporation

    Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

    Following an FDA approval of a second-line pancreatic cancer treatment, Immuneering Corporation reaffirmed its focus on first-line metastatic pancreatic cancer patients. The company is enrolling patients in its Phase 3 MAPKeeper 301 trial evaluating atebimetinib combined with chemotherapy. Previous Phase 2a data showed 17.3-month median overall survival with manageable side effects, with 84% of patients maintaining or gaining weight at three months.

    IMRX